Trimeris, Neokimia viral fusion deal

TRMS and Neokimia (Sherbrooke, Quebec) partnered to research and develop small molecule HIV fusion inhibitors. TRMS will screen a library of small molecules from Neokimia, which will optimize resulting leads. The companies will jointly select preclinical compound candidates. The partners initially will focus on the HIV gp41 fusion protein target, and TRMS has an option to select an additional target. The companies will share research costs, and TRMS will be responsible for clinical development and regulatory and commercial activities. Neokimia is eligible for milestones and royalties, and has an option to co-fund clinical development of resulting compounds through Phase I trials, in exchange for increased royalties. ...